Diabetes, a metabolic disease, is on the rise worldwide, and over 90% of cases are type 2 diabetes, where the body does not effectively respond to insulin.
Complaints such as pain in the Achilles tendon, tennis elbow, swimmer’s shoulder and jumper’s knee are familiar to many young sportspeople, as well as to older individuals. These conditions are all caused by overloading of tendons and are generally very painful.
About 20% of U.S. adults experience major depression in their lifetime. For most people, symptoms improve within a few treatment attempts, but up to one‐third of patients have treatment‐resistant depression, for which standard antidepressant medication or psychotherapy isn’t enough.
The human brain is complex. Understanding deep brain function usually requires the insertion of probes that frequently result in irreversible tissue damage. Current neural probes are made out of silicon, a brittle material that can shatter during placement.
UF Health Cancer Institute researchers have discovered a small compound produced naturally by gut bacteria that doubled the response to lung cancer immunotherapy treatment in mice and can now be made into a drug for testing in humans.
Nanoparticles are engineered to home in on areas where cartilage has degenerated in osteoarthritis, ensuring that treatment concentrates exactly where it is needed
IotaMotion announced today that it received FDA 510(k) clearance for expanded pediatric use of its iotaSoft insertion system.
Boston Scientific (NYSE: BSX)+
announced that it received CE mark approval for its Embold detachable coil system.
Heart disease remains the leading cause of death worldwide, yet progress in understanding and treating cardiac disorders is limited by the shortcomings of existing experimental models. Traditional animal models often fail to capture human-specific cardiac biology, while conventional two-dimensional cell cultures lack the functional and structural complexity of heart tissue.
A new international study led by researchers from UNSW Sydney’s Center for Healthy Brain Aging (CHeBA) has developed the first practical, five-year dementia risk prediction tool for stroke survivors—using only information that’s routinely collected in hospitals and clinics.